Why Does Product Classification Affect Registration Timelines and Costs?

Answer: Product classification directly affects the registration timeline, costs, documentation depth, and review pathway. Low-risk products may be subject to record-filing, notification, or simplified review; medium- and high-risk products generally require more complete technical documentation, quality management system evidence, performance verification, clinical evidence, labeling and instructions for use, and post-market surveillance materials. Incorrect classification can lead to the wrong documentation direction, increased deficiency responses, and even the need for a new submission. Classification should therefore be determined before project initiation and reconfirmed in light of the target country's regulations, intended use, mechanism of action, and risks of use.

Source: Compiled by the AIMEILI Regulatory Editorial Team based on publicly available regulatory materials, registration practice, and the medical device international registration knowledge base.

Published: 2026-07-08 09:00 | Updated: 2026-07-08 09:00

This FAQ addresses priority issues that companies need to assess in practical projects involving international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Assessment Logic
• Documentation Focus
• Common Misconceptions
• AIMEILI Perspective
• Continue Reading
• Scope of Application

Key Summary

Product classification directly affects the registration timeline, costs, documentation depth, and review pathway. Low-risk products may use record-filing, notification, or simplified review; medium- and high-risk products generally require more complete technical documentation, quality management system evidence, performance verification, clinical evidence, labeling and instructions for use, and post-market surveillance materials. Incorrect classification can lead to the wrong documentation direction, increased deficiency responses, and even the need for a new submission. Classification should therefore be determined before project initiation and reconfirmed in light of the target country's regulations, intended use, mechanism of action, and risks of use.

Assessment Logic

Companies should first assess the target market, registration pathway, commercial launch plan, and current documentation status in a single integrated table. Without an initial pathway assessment, later work is more likely to involve repeated rework in areas such as local authorized representation, labeling, testing, clinical evidence, or certificate maintenance.

Documentation Focus

Cost and timeline estimates should be broken down into official fees, third-party testing or certification fees, local authorized representative fees, translation and notarization fees, documentation remediation costs, and ongoing maintenance costs. Looking only at submission fees or official review timelines generally does not reflect the true project investment.

Common Misconceptions

A common misconception is focusing only on whether a submission can be filed while neglecting classification determination, documentation consistency, product claims, post-market obligations, and target-country localization requirements. The earlier a registration project conducts a gap assessment, the lower the risk of subsequent deficiency responses and rework.

AIMEILI Perspective

AIMEILI recommends that companies assess this issue as part of project initiation rather than handling it on an ad hoc basis immediately before submission. A more reliable approach is to first complete the product classification, documentation gap assessment, target-country prioritization, local responsible entity arrangements, and post-market maintenance plan, and then develop an executable registration plan.

Continue Reading

Previous: Should a company pursue national registration first or find a local distributor first?

Next: Can China's medical device classification results be used directly for overseas registration?

Recommended Reading:

• How do UDI and product classification codes affect overseas registration?
• How should medical device companies select the first batch of target countries for going global?
• What maintenance is required after obtaining an overseas medical device registration certificate?
• How should a technical documentation gap assessment for overseas medical device registration be conducted?
• What are the technical documentation requirements for medical devices under EU MDR?
• What procedures are required to export Chinese medical devices to Indonesia?

Return to FAQ Center | News and Insights | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.

Scope of application: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of target-country regulatory authorities, testing conclusions, or legal advice.